Simbryo
Simbryo Technologies, Inc.
Simbryo FX is the first test to directly measure your endometrium's ability to support implantation — giving patients and providers real answers instead of another cycle of uncertainty.
simbryotech.com · Houston, TX
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$5.3M of $5.3M
Filed2026-07-27
Days since filing69
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- Yes
- Date of first sale
- 2025-09-26
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Yael KatzExecutive Officer · Director
- Aryeh WarmflashExecutive Officer
- Stephen RooksDirector
- Andrea MazzocchiDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold12.2 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-241
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Head of CommercialSEP 25Cincinnati, Ohio · Full-time · open 9 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.